Patents by Inventor John Y. L. Chung

John Y. L. Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20180065973
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20180029981
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Application
    Filed: September 26, 2017
    Publication date: February 1, 2018
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for preparing chiral dipeptidyl peptidase-IV inhibitors
    Patent number: 9862725
    Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
  • Process for making beta 3 agonists and intermediates
    Patent number: 9822121
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for making beta 3 agonists and intermediates
    Patent number: 9809536
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 7, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS
    Publication number: 20170226146
    Abstract: The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Application
    Filed: February 8, 2017
    Publication date: August 10, 2017
    Inventors: John Y.L. Chung, Amude Kassim, John Limanto, Michael Shevlin, Peter E. Maligres, Daniel A. DiRocco, James F. Dropinski, Rose Mathew, Yi Ning Ji Chen, Edward C. Sherer, Mikhail Reibarkh, Artis Klapars, Alan Hyde, Susan L. Zultanski, Aaron Moment, Bryon Simmons, Tyler A. Davis, Timothy James Wright, Ralph Calabria, Louis Charles Campeau
  • PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS
    Publication number: 20170158701
    Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20160176884
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Crystalline polymorphic forms of an antidiabetic compound
    Patent number: 9315457
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: April 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: John Y. L. Chung
  • CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND
    Publication number: 20160075650
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Application
    Filed: March 26, 2015
    Publication date: March 17, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: JOHN Y. L. CHUNG
  • Crystalline polymorphic forms of an antidiabetic compound
    Patent number: 9272999
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: March 1, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Yanfeng Zhang, Aaron S. Cote, Jeremy Scott, Yekaterina Vaynshteyn
  • CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND
    Publication number: 20150197490
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Yanfeng Zhang, Aaron S. Cote, Jeremy Scott, Yekaterina Vaynshteyn
  • Crystalline polymorphic forms of an antidiabetic compound
    Patent number: 9012488
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20150087832
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: October 22, 2012
    Publication date: March 26, 2015
    Applicant: MERCK SHARP & DOHME, CORP.
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Liebermann, Zhuqing Liu, Joseph Lynch, Kevine M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20140242645
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions.
    Type: Application
    Filed: October 22, 2012
    Publication date: August 28, 2014
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND
    Publication number: 20140171480
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
  • Crystalline polymorphic forms of an antidiabetic compound
    Patent number: 8697740
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: April 15, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Jennifer Baxter, Aaron S. Cote, Yekaterina Vaynshteyn, Donal Desmond, Jeremy Scott
  • PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS
    Publication number: 20120053350
    Abstract: A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein PG1 is an amine protective group; k is 0, 1, or 2; and RU, R1, R2, and R3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (RU)3S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 1, 2012
    Inventors: Ian Mangion, Mark A. Huffman, Rebecca T. Ruck, Joseph Lynch, John Y.L. Chung, Benjamin Marcune
  • CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND
    Publication number: 20120010262
    Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
    Type: Application
    Filed: January 8, 2010
    Publication date: January 12, 2012
    Inventors: John Y.L. Chung, Yanfeng Zhang, Laura Artino, Jennifer Baxter, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
  • Process for the synthesis of gonadotropin releasing hormone antagonists
    Patent number: 6620824
    Abstract: The present invention relates to a process for preparing a compound of gonadotropin releasing hormone antagonists having a Formula I, in an efficient way, which involves preparation of key intermediates: 2-arylindole core; a chiral aziridine, in particular chiral nosyl aziridine; and an amine salt. The key process involves the coupling reaction of 2-arylindole and nosyl aziridine under boron trifluoride catalysis, which provides the final compound with unprecedented regioselectivity and enantioselectivity.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 16, 2003
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, Roger N. Farr, Guy R. Humphrey